These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 7804814)
1. U.S. v. Barr Laboratories: a technical perspective. Madsen RE PDA J Pharm Sci Technol; 1994; 48(4):176-9. PubMed ID: 7804814 [No Abstract] [Full Text] [Related]
2. Enforcement of the current good manufacturing practices for solid oral dosage forms after United States v. Barr Laboratories. Jimenez FA Food Drug Law J; 1997; 52(1):67-82. PubMed ID: 10346711 [No Abstract] [Full Text] [Related]
3. Report suggests steps to improve safety of drug supply. Traynor K Am J Health Syst Pharm; 2011 Sep; 68(17):1570, 1574. PubMed ID: 21856799 [No Abstract] [Full Text] [Related]
4. Secondary wholesalers oppose FDA pedigree regulation. Young D Am J Health Syst Pharm; 2001 Sep; 58(18):1698, 1700. PubMed ID: 11571811 [No Abstract] [Full Text] [Related]
5. US drug shortages are set to reach record high in 2011, report says. Tanne JH BMJ; 2011 Dec; 343():d8307. PubMed ID: 22194406 [No Abstract] [Full Text] [Related]
6. Safe drugs and the cost of good intentions. Eichler HG; Abadie E; Raine JM; Salmonson T N Engl J Med; 2009 Apr; 360(14):1378-80. PubMed ID: 19339718 [No Abstract] [Full Text] [Related]
7. Realizing two-tiered innovation policy through drug regulation. Ridgway WE Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807 [No Abstract] [Full Text] [Related]
8. Regulating the safety of pharmaceuticals: the FDA, preemption, and the public's health. Gostin LO JAMA; 2009 May; 301(19):2036-7. PubMed ID: 19454642 [No Abstract] [Full Text] [Related]
9. Toward more effective drug regulation. Schmidt AM FDA Consum; 1975 Dec-1976 Jan; 9(10):27-9. PubMed ID: 10316532 [No Abstract] [Full Text] [Related]
10. The HEALTH Act's FDA defense to punitive damages: a gift to drug makers or to the public? Levy E Fordham Law Rev; 2006 Mar; 74(4):2425-60. PubMed ID: 17115481 [No Abstract] [Full Text] [Related]
11. Regulatory and quality considerations for continuous manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium. Allison G; Cain YT; Cooney C; Garcia T; Bizjak TG; Holte O; Jagota N; Komas B; Korakianiti E; Kourti D; Madurawe R; Morefield E; Montgomery F; Nasr M; Randolph W; Robert JL; Rudd D; Zezza D J Pharm Sci; 2015 Mar; 104(3):803-12. PubMed ID: 25830179 [TBL] [Abstract][Full Text] [Related]
12. Upon closer inspection. As the U.S. imports more drugs and devices, the FDA's overseas initiatives aim to head off trouble at the source. Rhea S Mod Healthc; 2009 Mar; 39(13):28-30. PubMed ID: 19405431 [No Abstract] [Full Text] [Related]
13. Prescription drug advertising--should states regulate what is false and misleading? Shaeffer J Food Drug Law J; 2003; 58(4):629-48. PubMed ID: 15027454 [No Abstract] [Full Text] [Related]
14. Human and veterinary drugs: good manufacturing practices and proposed exemptions for certain OTC products. Fed Regist; 1978 Sep; 43(190 Pt 2):45013-89. PubMed ID: 10316700 [No Abstract] [Full Text] [Related]
15. The learned intermediary doctrine: past, present and future. Alsobrook HB Leg Med; 1994; ():269-80. PubMed ID: 7830482 [No Abstract] [Full Text] [Related]